GLP 2 (TZ) 10 & 30mg
Tirzepatide (GLP-2) is a synthetic peptide and dual GIP/GLP-1 receptor agonist designed from incretin peptide sequences and modified with a fatty-acid side chain. Also known as LY3298176, it is studied for GIPR and GLP-1R signaling, glucose metabolism, insulin signaling, energy balance, lipid metabolism, and metabolic regulation. Research areas include incretin biology, metabolic research, endocrinology, receptor pharmacology, and peptide-receptor interactions..
Compound information
What is GLP-2 (Tirz)?
The first peptide built to switch on two incretin receptors at once, GIP and GLP-1, from a single molecule. Based on the natural GIP hormone and engineered to last far longer in the body, it serves as the benchmark dual-agonist research tool.
GLP-2 (Tirz) structure
Stability information
Product overview
A first-in-class dual incretin agonist supplied for laboratory evaluation at a ≥99% HPLC analytical standard.
Technical overview
Tirzepatide (GLP-2) is a 39-amino-acid linear peptide derived from the native GIP sequence, engineered so a single molecule engages the GIP and GLP-1 receptors together. An Aib substitution at position 2 blocks DPP-4 breakdown, while a C20 fatty diacid chain extends its half-life.
It is produced by solid-phase synthesis and preparative purification, then released against a lot-matched Certificate of Analysis carrying HPLC purity and LC-MS identity.
Research applications
Laboratories apply Tirzepatide across cAMP accumulation assays in HEK293 cells expressing GIPR or GLP-1R, insulin-secretion work in beta-cell lines carrying both receptors, and rodent feeding and energy-expenditure studies. Its dual mechanism makes it the reference point for separating GIP-driven effects from GLP-1-driven ones against GLP-1 (Sema) and GLP-3 (RT).
Kylo Peptides supplies this compound as a reference material for scientific inquiry. All applications must be conducted by qualified professionals in controlled laboratory environments. It has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease.
Frequently Researched Together
Frequently Asked Questions
Its defining feature is dual activity. Where GLP-1 (Sema) engages only the GLP-1 receptor, GLP-2 (Tirz) switches on both GIP and GLP-1 receptors from one molecule. That combination lets researchers study how the two incretin pathways interact rather than examining either one in isolation.
Kylo GLP-2 (Tirz) is supplied at ≥99% purity by HPLC, with identity verified through LC-MS. Every lot passes independent third-party testing before release, and the matching certificate is published against the lot number shown on the vial.
GLP-2 (Tirz) carries the CAS number 2023788-19-2 and the development code LY3298176. Its molecular formula is C225H348N48O68, with a molecular weight near 4813.45 g/mol and a chain of 39 amino acids.
Store the lyophilized powder frozen at −20 °C, sealed against light and moisture, with −80 °C suited to long-term holding. Because the peptide readily absorbs water, keep its exposure to open air brief. Once reconstituted, refrigerate at 2 to 8 °C and use within a validated window.
No. This GLP-2 (Tirz) is prepared strictly for in vitro laboratory research. It is not formulated or labeled for use in people or animals, and it does not stand in for any FDA-approved product.
The Tirzepatide molecule is the active compound in FDA-approved prescription medicines from Eli Lilly. The material offered here is research-grade and sold for laboratory work alone. Kylo operates as a chemical supplier, not a compounding pharmacy under section 503A or 503B.
Backed By A Lot-Matched COA
Every GLP-2 (Tirz) order is tied to a certificate of analysis matched to the exact lot in your vial.
Shop catalog →
